Skip to content
CompoundSci
All peptides
Research vial labelled Adipotide, a Fat loss and metabolic peptide studied in preclinical and clinical literature

Adipotide

FTPP

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Primate studies showed dose-dependent kidney toxicity. This is the compound on the list with the clearest documented harm signal.

General profile

Class
Fat loss and metabolic
Evidence
Early or preclinical only
Studied dose range
Rodent-scaled only, no human range established
Frequency in protocols
Short courses in animal studies
Route
Subcutaneous
Half life
Short
Reconstitution
2 mL bacteriostatic water per 10 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Short courses only, per study design

Primate work showed dose-dependent kidney toxicity. Nothing here supports an ongoing schedule of any kind.

Reported cycle: 2 weeks on, 8 weeks off

Primate studies ran short courses and still produced dose-dependent kidney damage.

Watch for: Any change in urine output or colour, swelling, or thirst. This is the clearest documented harm signal on the site.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

No named pair conflicts are on file for this compound. That is missing data, not clearance: with no compatibility data the default is separate syringes, and you still introduce one new compound at a time.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Adipotide fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature